CHSY3 and lung adenocarcinoma: Pan-cancer differential expression analysis revealed that CHSY3 was significantly differentially expressed in various cancers, with significant down-regulation in glioblastoma multiforme, lung adenocarcinoma, lung squamous carcinoma, etc., and significant up-regulation in STAD, breast-invasive carcinoma, kidney renal clear cell carcinoma, etc. (p-value < 0.05, Figure 1A).